CSL Stock Overview
Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
CSL Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$278.79 |
| 52 Week High | AU$313.55 |
| 52 Week Low | AU$265.14 |
| Beta | 0.31 |
| 1 Month Change | 2.74% |
| 3 Month Change | -5.06% |
| 1 Year Change | -1.32% |
| 3 Year Change | -4.47% |
| 5 Year Change | -1.24% |
| Change since IPO | 34,749.10% |
Recent News & Updates
With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case
Nov 01
We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt
Oct 05CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances
Sep 18Recent updates
With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case
Nov 01We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt
Oct 05CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances
Sep 18Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely
Sep 03CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 16An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued
Aug 07CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings
May 22An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued
May 01Does CSL (ASX:CSL) Have A Healthy Balance Sheet?
Mar 19CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors
Feb 02Shareholder Returns
| CSL | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0.2% | 1.4% | -0.6% |
| 1Y | -1.3% | 4.2% | 9.1% |
Return vs Industry: CSL underperformed the Australian Biotechs industry which returned 4.2% over the past year.
Return vs Market: CSL underperformed the Australian Market which returned 9.1% over the past year.
Price Volatility
| CSL volatility | |
|---|---|
| CSL Average Weekly Movement | 2.2% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: CSL has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CSL's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1916 | 32,698 | Paul McKenzie | www.csl.com.au |
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
CSL Limited Fundamentals Summary
| CSL fundamental statistics | |
|---|---|
| Market cap | AU$136.66b |
| Earnings (TTM) | AU$4.24b |
| Revenue (TTM) | AU$23.77b |
31.8x
P/E Ratio5.7x
P/S RatioIs CSL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSL income statement (TTM) | |
|---|---|
| Revenue | US$14.80b |
| Cost of Revenue | US$7.10b |
| Gross Profit | US$7.71b |
| Other Expenses | US$5.06b |
| Earnings | US$2.64b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 10, 2025
| Earnings per share (EPS) | 5.46 |
| Gross Margin | 52.06% |
| Net Profit Margin | 17.85% |
| Debt/Equity Ratio | 54.2% |
How did CSL perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield48%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 07:04 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CSL Limited is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | APP Securities Pty Ltd. |
| Russell Wright | Barclay Pearce Capital Pty Limited |
| Saul Hadassin | Barrenjoey Markets Pty Limited |